The Adenosinergic System : A Non-Dopaminergic Target in Parkinson's Disease / edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.

Format:

Book

Contributor:

Morelli, Micaela, editor.

Simola, Nicola, editor.

Wardas, Jadwiga, editor.

SpringerLink (Online service)

Series:

Current topics in neurotoxicity 2363-9563 ; 10.

Current Topics in Neurotoxicity, 2363-9563 ; 10

Language:

English

Subjects (All):

Medicine.

Neurosciences.

Neurology.

Physical Description:

1 online resource.

Edition:

First edition 2015.

Contained In:

Springer eBooks

Place of Publication:

Cham : Springer International Publishing : Imprint: Springer, 2015.

System Details:

Mode of Access: World Wide Web.

text file PDF

Summary:

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.

Contents:

Adenosine A2A receptors: localization and function

Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer

Adenosine A2A receptor antagonists in drug development

Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease

Role of adenosine A2A receptors in the control of neuroinflammation - relevance for Parkinson's disease

Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection

Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson's disease in preclinical studies

Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism

Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations

Adenosine A2A receptor-mediated control of non-motor functions in Parkinson's disease

Imaging Studies with A2A Receptor Antagonists

Caffeine and neuroprotection in Parkinson's disease

The story of istradefylline - the first approved A2A antagonist for the treatment of Parkinson's disease

Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease

Adenosinergic regulation of sleep-wake behavior in the basal ganglia.

Other Format:

Printed edition:

ISBN:

9783319202730

Access Restriction:

Restricted for use by site license.